Synthetic Biologics to Present at the 28th Annual ROTH Conference

ROCKVILLE, Md., March 9, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to present at the 28th Annual ROTH Conference being held March 14-16 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Wednesday, March 16, 2016 at 8:30 a.m. (Pacific Time)/11:30 a.m. (Eastern Time).  

Synthetic Biologics, Inc. (PRNewsFoto/Synthetic Biologics, Inc.)

A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the web at After the presentation, a replay will be archived and accessible for 60 days at the same website.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company’s lead candidates in Phase 2 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C) and (2) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). In collaboration with Intrexon Corporation (NYSE: XON), the Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of Pertussis and discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics’ website at              

Logo –

To view the original version on PR Newswire, visit:

SOURCE Synthetic Biologics, Inc.